Cargando…

Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer

We wanted to study cyclin A as a marker for prognosis and chemotherapy response. A total of 283 women with metastatic breast cancer were initially enrolled in a randomised multicentre trial comparing docetaxel to sequential methotrexate-fluorouracil (MF) in advanced breast cancer after anthracycline...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poikonen, P, Sjöström, J, Amini, R-M, Villman, K, Ahlgren, J, Blomqvist, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361595/ https://www.ncbi.nlm.nih.gov/pubmed/16091759 http://dx.doi.org/10.1038/sj.bjc.6602735

Ejemplares similares

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
por: Poikonen, P, et al.
Publicado: (1999)

Biological Markers and Response to Neoadjuvant Taxane-Based Chemotherapy in Patients with Locally Advanced Breast Cancer
por: El-sayed, Mohamed I., et al.
Publicado: (2012)

Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer
por: Batista, N, et al.
Publicado: (2004)

Immune gene expression and response to chemotherapy in advanced breast cancer
por: Foukakis, Theodoros, et al.
Publicado: (2018)

Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer
por: Hackshaw, A, et al.
Publicado: (2005)

Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy
por: Bernhard, J, et al.
Publicado: (2010)

The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study
por: Gormley, J A, et al.
Publicado: (2011)

HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review
por: Carlsson, J, et al.
Publicado: (2004)

A Pilot Study to Investigate the Role of Thymidylate Synthase as a Marker of Prognosis for Neoadjuvant Chemotherapy in Gastric and Gastro-Oesophageal Junction Adenocarcinoma
por: Mirza, A., et al.
Publicado: (2013)

Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Meattini, Icro, et al.
Publicado: (2014)

Predicting response and survival in chemotherapy-treated triple-negative breast cancer
por: Prat, A, et al.
Publicado: (2014)

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies
por: Bahleda, Rastislav, et al.
Publicado: (2017)

Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer
por: Akslen, L A, et al.
Publicado: (2011)

Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG)
por: Cold, S, et al.
Publicado: (2005)

Serum Oxidative Stress Markers and Genotoxic Profile Induced by Chemotherapy in Patients with Breast Cancer: A Pilot Study
por: Júnior, Antonio Luiz Gomes, et al.
Publicado: (2015)

Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer
por: Mukherjee, A, et al.
Publicado: (2010)

Side effects during chemotherapy predict tumour response in advanced colorectal cancer
por: Schuell, B, et al.
Publicado: (2005)

The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis
por: Zhang, Wei, et al.
Publicado: (2017)

High cyclin B1 expression is associated with poor survival in breast cancer
por: Aaltonen, K, et al.
Publicado: (2009)

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177
por: Chen, E X, et al.
Publicado: (2014)

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer
por: Lee, C K, et al.
Publicado: (2010)

The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication
por: Hooper, C E, et al.
Publicado: (2015)

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006)

Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
por: Myklebust, M P, et al.
Publicado: (2012)

Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy – a longitudinal study
por: Harvie, M N, et al.
Publicado: (2005)

The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients
por: Tampellini, M, et al.
Publicado: (2006)

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies
por: Mita, Monica M, et al.
Publicado: (2017)

Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
por: Tanioka, M, et al.
Publicado: (2010)

Assessment of skin response in T4b breast carcinoma patients post-neoadjuvant chemotherapy
por: Sharma, Abhishek, et al.
Publicado: (2021)

The Resistive Index Is a Marker of Renal Function, Pathology, Prognosis, and Responsiveness to Steroid Therapy in Chronic Kidney Disease Patients
por: Hanamura, Kikuno, et al.
Publicado: (2012)

Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival
por: Nisman, B, et al.
Publicado: (2008)

A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer.
por: Sjöström, J., et al.
Publicado: (1998)

Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer
por: Dose-Schwarz, J, et al.
Publicado: (2010)

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
por: Rigter, L S, et al.
Publicado: (2013)

HLA Markers for Poor Prognosis in Systemic Sclerosis Brazilian Patients
por: Del Rio, Ana Paula Toledo, et al.
Publicado: (2013)

Chemotherapy and prognosis in advanced thymic carcinoma patients
por: Song, Zhengbo, et al.
Publicado: (2015)

Tumour microvessel density as predictor of chemotherapy response in breast cancer patients
por: Tynninen, O, et al.
Publicado: (2002)

Cyclin D1, cyclin E, and p21 have no apparent prognostic value in anal carcinomas treated by radiotherapy with or without chemotherapy
por: Allal, A S, et al.
Publicado: (2004)

Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer?
por: Evans, A, et al.
Publicado: (2013)

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques
por: Heil, Joerg, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8vqrc4e9g5oa56p55pqkpc1ai5